Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Glypharma

Glypharma
2012 FOUNDED
M&A STATUS
1-10 EMPLOYEES
M&A LATEST DEAL TYPE
Description

Developer of novel clinical therapies designed for short bowel syndrome and other rare gastrointestinal diseases. The company's therapies include a novel proprietary Glucagon-Like Peptide-2 (GLP-2) analogue, enabling patients to get hematological malignancies for myelotoxic therapies.

Ownership Status
Acquired/Merged
(Operating Subsidiary)
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Other Industries
Other Pharmaceuticals and Biotechnology
Parent Company
Primary Office
  • 1188 Union
  • Suite 504
  • Montreal, Quebec H3B 0E5
  • Canada

+1 (514) 000-0000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Glypharma’s full profile, request a free trial.

Glypharma Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Merger/Acquisition 09-Oct-2018 0000 Completed Pre-Clinical Trials
1. Early Stage VC 05-Oct-2012 0000 0000 Completed Pre-Clinical Trials
To view this company’s complete deal history including valuation and funding, request access »

Glypharma Competitors (19)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Amgen Formerly PE-Backed Thousand Oaks, CA 00000 00.000 000000000000 00.000
0000 000000 Formerly VC-backed Santa Monica, CA 000 00000 000000&0 00000
00000000 000000 00 Venture Capital-Backed Louisville, KY 000.00 0000000000 000.00
0000 00000000000 Venture Capital-Backed Cambridge, MA 00 00000 00000000000 00000
00000 000000000000 Formerly VC-backed New York, NY 00 000.00 000000000000 000.00
To view this company’s complete list of competitors, request access »

Glypharma Former Investors (3)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
CTI Life Sciences Fund Venture Capital Minority 000 0000 000000 0
Ferring International Center Corporation Minority 000 0000 000000 0
Fonds de solidarité FTQ PE/Buyout Minority 000 0000 000000 0

Glypharma Executive Team (2)

Name Title Board
Seat
Contact
Info
Micheline Beauvais Director, Finance
Jean-Francois Leprince Interim Chief Executive Officer & Board Member

Glypharma Board Members (6)

Name Representing Role Since Contact
Info
Gaétan Gravel Self Board Member 000 0000
Jean-Francois Leprince Self Interim Chief Executive Officer & Board Member 000 0000
Michael Seckler Self Board Member 000 0000
Pierre Lapalme Self Chairman 000 0000
Thomas Schuetz Ph.D Self Board Member 000 0000

1 Former Board Member

You’re viewing 5 of 6 board members. Get the full list »